Insulet Collaborates with Samsung to Deliver Galaxy Smartphone-Controlled Insulin Pump Delivery System
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it is collaborating with Samsung Electronics America, Inc. for a Samsung Galaxy smartphone-controlled Omnipod System. Once approved, the system will be the first device providing consumers the ability to use their personal Galaxy smartphone1 to securely control their insulin pump therapy.
The Samsung Knox mobile security platform is built into all Samsung mobile devices and is comprised of overlapping defense and security mechanisms to protect against cybersecurity risks. Insulet’s FDA-cleared Omnipod DASH™ Insulin Management System (Omnipod DASH System) has been designed as an app on a locked-down mobile phone incorporating state-of-the-art security features. The Knox platform complements the Omnipod DASH System security features by verifying the integrity of the Samsung mobile device through a series of security checks starting from the hardware level and extending through the operating system, creating a highly-secure platform. This will allow users to securely operate their Omnipod System from their smartphone.
“Over the last few years, there have been many exciting advancements that allow individuals to experience how phone control could improve their diabetes management,” said Shacey Petrovic, President and Chief Operating Officer. “For us, because we are delivering a life-sustaining drug, it’s critical that we have the highest measures of safety and security in place. We are thrilled to work with Samsung, the global leader in smartphones, to lead the way in offering phone control of an insulin pump in a way that is simple, safe and secure.”
“By integrating Samsung smartphones with drug delivery medical devices like Insulet’s Omnipod System, we’ve demonstrated that consumer-based digital health technologies can not only monitor and track one’s condition, but they can enable patient control of medical treatments,” said Dr. David Rhew, Chief Medical Officer and VP/GM for Enterprise Healthcare, Samsung Electronics America. “As chronic conditions like diabetes continue to increase in prevalence across all demographics, integrated partnerships between consumer technology and medical device companies, with support from regulators, will help establish a new paradigm of consumerism in healthcare in which medical care adapts to consumer lifestyle and preference.”
1 Capabilities will be limited to select Samsung Galaxy smartphone models. Information on exact model availability will be shared at a later date.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. Founded in 2000, more than 150,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives.
On July 1, Insulet assumed direct operations of its Omnipod Insulin Management System product line in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as Insulet does in the United States and Canada.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 22, 2018 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
© 2018 Insulet Corporation. DASH, Omnipod and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005538/en/